Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2

14 Apr 2025

Abstract excerpt

This review systematically revises adenovirus (Ad) biology, vector structure, immune responses, and currently available Ad vector COVID-19 vaccines. It analyzes the challenges associated with the Ad vector-based vaccines, including preexisting vector immunity and other side effects. Moreover, this review explores novel and innovative strategies to overcome these constraints for developing next-generation vaccines...

Topics

Join the communities discussing this publication.

Animal Virus Infections Studies
SARS-CoV-2 and COVID-19 Research
Virus-based gene therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40333307
DOI: 10.3390/vaccines13040406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2PMID 40333307Read ↗

The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 VaccineSemantic proximity Read ↗

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral VectorsSemantic proximity Read ↗

State‐of‐the‐art human adenovirus vectorology for therapeutic approachesSemantic proximity Read ↗

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical ApplicationsSemantic proximity Read ↗

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccineSemantic proximity Read ↗

Adenovirus vector-based vaccine for infectious diseasesSemantic proximity Read ↗

Adenoviruses as gene/vaccine delivery vectors: promises and pitfallsSemantic proximity Read ↗

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectorsSemantic proximity Read ↗

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive ReviewSemantic proximity Read ↗

Adenoviral Vector Immunity: Its Implications and Circumvention StrategiesSemantic proximity Read ↗

Human adenovirus type 26 basic biology and its usage as vaccine vectorSemantic proximity Read ↗

Simian Adenoviruses As Vaccine VectorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.